Cargando…
Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma
While cancer immunotherapy has been remarkably successful in some malignancies, some cancers derive limited benefit from current immunotherapies. Here, we combined immune landscape signatures with hepatocellular carcinoma clinical and prognostic features to classify them into distinct subtypes. The...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732284/ https://www.ncbi.nlm.nih.gov/pubmed/33049716 http://dx.doi.org/10.18632/aging.103977 |
_version_ | 1783622059008458752 |
---|---|
author | Yan, Hongmei Chen, Yuchuan Wang, Kai Yu, Lu Huang, Xixin Li, Qianyu Xie, Yuwen Lin, Jiayu He, Yueyun Yi, Xinyu Wang, Yanzhi Chen, Longhua Ding, Yi Li, Yiyi |
author_facet | Yan, Hongmei Chen, Yuchuan Wang, Kai Yu, Lu Huang, Xixin Li, Qianyu Xie, Yuwen Lin, Jiayu He, Yueyun Yi, Xinyu Wang, Yanzhi Chen, Longhua Ding, Yi Li, Yiyi |
author_sort | Yan, Hongmei |
collection | PubMed |
description | While cancer immunotherapy has been remarkably successful in some malignancies, some cancers derive limited benefit from current immunotherapies. Here, we combined immune landscape signatures with hepatocellular carcinoma clinical and prognostic features to classify them into distinct subtypes. The immunogenomic profiles, stromal cell features and immune cell composition of the subtypes were then systematically analyzed. Two independent prognostic indexes were established based on 6 immune-related genes and 17 differentially expressed genes associated with stromal cell content. These indexes were significantly correlated with tumor mutation burden, deficient DNA mismatch repair and microsatellite instability. In addition, tumor-infiltrating lymphocytes, including activated NK cells, resting memory CD4 T-cells, eosinophils, and activated mast cells were significantly correlated with hepatocellular carcinoma survival. In conclusion, we have comprehensively described the immune landscape signatures and identified prognostic immune-associated biomarkers of hepatocellular carcinoma. Our findings highlight potential novel avenues for improving responses to immunotherapy. |
format | Online Article Text |
id | pubmed-7732284 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Impact Journals |
record_format | MEDLINE/PubMed |
spelling | pubmed-77322842020-12-18 Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma Yan, Hongmei Chen, Yuchuan Wang, Kai Yu, Lu Huang, Xixin Li, Qianyu Xie, Yuwen Lin, Jiayu He, Yueyun Yi, Xinyu Wang, Yanzhi Chen, Longhua Ding, Yi Li, Yiyi Aging (Albany NY) Research Paper While cancer immunotherapy has been remarkably successful in some malignancies, some cancers derive limited benefit from current immunotherapies. Here, we combined immune landscape signatures with hepatocellular carcinoma clinical and prognostic features to classify them into distinct subtypes. The immunogenomic profiles, stromal cell features and immune cell composition of the subtypes were then systematically analyzed. Two independent prognostic indexes were established based on 6 immune-related genes and 17 differentially expressed genes associated with stromal cell content. These indexes were significantly correlated with tumor mutation burden, deficient DNA mismatch repair and microsatellite instability. In addition, tumor-infiltrating lymphocytes, including activated NK cells, resting memory CD4 T-cells, eosinophils, and activated mast cells were significantly correlated with hepatocellular carcinoma survival. In conclusion, we have comprehensively described the immune landscape signatures and identified prognostic immune-associated biomarkers of hepatocellular carcinoma. Our findings highlight potential novel avenues for improving responses to immunotherapy. Impact Journals 2020-10-13 /pmc/articles/PMC7732284/ /pubmed/33049716 http://dx.doi.org/10.18632/aging.103977 Text en Copyright: © 2020 Yan et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Yan, Hongmei Chen, Yuchuan Wang, Kai Yu, Lu Huang, Xixin Li, Qianyu Xie, Yuwen Lin, Jiayu He, Yueyun Yi, Xinyu Wang, Yanzhi Chen, Longhua Ding, Yi Li, Yiyi Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma |
title | Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma |
title_full | Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma |
title_fullStr | Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma |
title_full_unstemmed | Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma |
title_short | Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma |
title_sort | identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732284/ https://www.ncbi.nlm.nih.gov/pubmed/33049716 http://dx.doi.org/10.18632/aging.103977 |
work_keys_str_mv | AT yanhongmei identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma AT chenyuchuan identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma AT wangkai identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma AT yulu identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma AT huangxixin identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma AT liqianyu identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma AT xieyuwen identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma AT linjiayu identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma AT heyueyun identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma AT yixinyu identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma AT wangyanzhi identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma AT chenlonghua identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma AT dingyi identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma AT liyiyi identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma |